

**CURRICULUM VITAE**  
**Christopher Pope Elco MD, PhD**

Business Address                          Department of Pathology  
    Rhode Island Hospital  
    593 Eddy Street  
    Providence, RI  
Business Telephone:                      (401) 444-6127  
Cell:                                         (717) 991-3879  
Email:                                        [christopher.elco@lifespan.org](mailto:christopher.elco@lifespan.org)

---

**EDUCATION**

1994-1998	Bachelor of Science in Molecular Biophysics and Biochemistry Yale University New Haven, CT
1999-2008	Medical Scientist Training Program Case Western Reserve University Cleveland, OH
2006	Doctor of Philosophy in Molecular Virology Case Western Reserve University Cleveland, OH
2008	Doctor of Medicine Case Western Reserve University Cleveland, OH

**POSTGRADUATE TRAINING**

2013-2015	Post-doctoral Research Fellow Departments of Pathology and Dermatology Brigham and Women's Hospital Boston, MA
2012-2013	Harvard Dermatopathology Fellowship Brigham and Women's Hospital-based (including time spent at Massachusetts General Hospital and Beth Israel Deaconess Medical Center) Boston, MA

**CURRICULUM VITAE**  
**Christopher Pope Elco MD, PhD**

**POSTGRADUATE TRAINING (continued)**

- |           |   |
|-----------|---|
| 2011-2012 | infectious diseases, and head and neck pathology                                    |
| 2010-2011 | Hematopathology Fellowship  |
| 2008-2010 | Residency in Anatomic Pathology; time serving as fellow in divisions of soft tissue |

**PROFESSIONAL LICENSES AND BOARD CERTIFICATION**

**Medical Licensure**

- |              |                         |
|--------------|-------------------------|
| 2015-present | Rhode Island (MD15191)  |
| 2015-2017    | Massachusetts (262572)  |
| 2013-2016    | Pennsylvania (MD448489) |

**Board Certification**

- |      |   |
|------|---|
| 2013 | Diplomate, American Board of Pathology<br>(Certification in Anatomic Pathology) |
| 2014 | Subspecialty certification in Dermatopathology                                  |
| 2014 | Subspecialty certification in Hematology  |

**ACADEMIC APPOINTMENTS**

- |              |  |
|--------------|--|
| 2016-present | Assistant Professor of Pathology<br>Warren Alpers Medical School of Brown University<br>Providence, RI |
| 2010-2016    | Clinical and Research Fellow, Harvard Medical School,<br>Boston, MA                                    |

**HOSPITAL APPOINTMENTS**

- |              |   |
|--------------|---|
| 2016-present | Associate Pathologist<br>Department of Pathology and Laboratory Medicine<br>Rhode Island Hospital, Providence, RI |
| 2015         | Associate Pathologist, Department of Pathology<br>Brigham and Women's Hospital<br>Boston, MA                      |

**CURRICULUM VITAE**  
**Christopher Pope Elco MD, PhD**

**ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS**

1. Brown CR, McCann JA, Hung GG, **Elco CP**, Chiang HL. Vid22p, a novel plasma membrane protein, is required for the fructose-1,6-bisphosphatase degradation pathway. *J Cell Sci.* 2002 Feb 1;115(Pt 3):655-666. PMID: 11861771.
2. Sarkar SN, Peters KL, **Elco CP**, Sakamoto S, Pal S, Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. *Nat Struct Mol Biol.* 2004 Nov;11(11):1060-1067. Epub 2004 Oct 24. PMID: 15502848.
3. **Elco CP**, Guenther JM, Williams BR, Sen GC. Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-kappaB, and interferon but not toll-like receptor 3. *J Virol.* 2005 Apr;79(7):3920-3929. PMID: 15767394.
4. Sarkar SN, Kessler SP, Rowe TM, Pandey M, Ghosh A, **Elco CP**, Hartmann R, Pal S, Sen GC. Natural mutations in a 2'-5' oligoadenylate synthetase transgene revealed residues essential for enzyme activity. *Biochemistry.* 2005 May 10;44(18):6837-43. PMID: 15865429.
5. Sarkar SN, **Elco CP**, Peters KL, Chattopadhyay S, Sen GC. Two tyrosine residues of Toll-like receptor 3 trigger different steps of NF- $\kappa$ B activation. *J Biol Chem.* 2007 Feb 9;282(6):3423-3427. Epub 2006 Dec 18. PMID: 17178723.
6. **Elco CP**, Sen GC. STAT1 required for interferon-inducible but not constitutive responsiveness to extracellular dsRNA. *J Interferon Cytokine Res.* 2007 May;27(5):411-423. PMID: 17523873.
7. Pavelitz T, Bailey AD, **Elco CP**, Weiner AM. Human U2 snRNA genes exhibit a persistently open transcriptional state and promoter disassembly at metaphase. *Mol Cell Biol.* 2008 Jun;28(11):3573-3588. doi: 10.1128/MCB.00087-08. Epub 2008 Mar 31. PMID: 18378697.
8. **Elco CP**, Mariño-Enriquez A, Abraham JA, Dal Cin P, Hornick JL. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. *Am J Surg Pathol.* 2010 Nov;34(11):1723-1727. doi: 10.1097/PAS.0b013e3181f17d51. PMID: 20871391.
9. Giardino AA, O'Regan K, Jagannathan JP, **Elco C**, Ramaiya N, LaCasce A. Richter's transformation of chronic lymphocytic leukemia. *J Clin Oncol.* 2011 Apr 1;29(10):e274-6. doi: 10.1200/JCO.2010.32.6579. Epub 2011 Jan 10. PMID: 21220587.
10. Hure MC, **Elco CP**, Ward D, Hutchinson L, Meng X, Dorfman DM, Yu H. Histiocytic sarcoma arising from clonally related mantle cell lymphoma. *J Clin Oncol.* 2012 Feb 10;30(5):e49-53. doi: 10.1200/JCO.2011.38.8553. Epub 2011 Dec 19. PMID: 22184374.

**CURRICULUM VITAE**  
**Christopher Pope Elco MD, PhD**

**ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS (continued)**

11. Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, **Elco CP**, Huang V, Matos TR, Kupper TS, Clark RA. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. *Sci Transl Med.* 2015 Mar 18;7(279):279ra39. doi: 10.1126/scitranslmed.3010302. PMID: 25787765.
12. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, **Elco CP**, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenegger W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. *Cell.* 2015 Sep 10;162(6):1242-1256. doi: 10.1016/j.cell.2015.08.052. PMID: 26359984.
13. Kirsch IR, Watanabe R, O'Malley JT, Williamson DW, Scott LL, **Elco CP**, Teague JE, Gehad A, Lowry EL, LeBoeuf NR, Krueger JG, Robins HS, Kupper TS, Clark RA. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. *Sci Transl Med.* 2015 Oct 7;7(308):308ra158. doi: 10.1126/scitranslmed.aaa9122. PMID: 26446955.
14. Kleffel S, Lee N, Lezcano C, Wilson BJ, Sobolewski K, Saab KR, Mueller H, Zhan Q, Posch C, **Elco CP**, DoRosario A, Garcia SS, Thakuria M, Wang YE, Wang LC, Murphy GF, Frank MH, Schatton T. ABCB5-targeted chemoresistance reversal inhibits Merkel cell carcinoma growth. *J Invest Dermatol.* 2016 Apr;136(4):838-46. doi: 10.1016/j.jid.2015.12.038. Epub 2016 Jan 29. PMID: 26827764.
15. Hui Y, **Elco CP**, Heinl NF, Lourenco AP, Wiggins DL, Wang Y. Diffuse dermal angiomyomatosis mimicking inflammatory breast carcinoma. *Breast J.* 2018 Mar;24(2):196-198. doi: 10.1111/tbj.12866. Epub 2017 Jul 26. PMID: 28744985.
16. de Masson A, O'Malley JT, **Elco CP**, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS. High-throughput sequencing of the T cell receptor  $\beta$  gene identifies aggressive early-stage mycosis fungoides. *Sci Transl Med.* 2018 May 9;10(440). pii: eaar5894. doi: 10.1126/scitranslmed.aar5894. PMID: 29743350.

**BOOKS AND BOOK CHAPTERS**

1. **Elco CP**, Sen GC. Interferon receptors. Volume 2, Encyclopedia of Biological Chemistry, 1<sup>st</sup> Ed. In: Lennarz WJ, Lane MD, Eds. Academic Press, pp 446-451, 2004.

**CURRICULUM VITAE**  
**Christopher Pope Elco MD, PhD**

**BOOKS AND BOOK CHAPTERS (continued)**

2. **Elco CP.** Multiple chapters –  
B. Cutaneous marginal zone lymphoma, p 106;  
Primary cutaneous follicle center lymphoma, pp 116-117;  
Primary cutaneous diffuse large B cell lymphoma, leg type, pp 129-130;  
1. Mature T-cell and NK-cell neoplasms: Mycosis fungoides, pp 152-155;  
Sézary syndrome, p 156;  
Primary cutaneous CD30+ T-cell lymphoproliferative disorders:  
A. Lymphomatoid papulosis (LYP), pp 157-158;  
B. Primary cutaneous anaplastic large cell lymphoma (ALCL), pp 159-160;  
Primary cutaneous  $\gamma\delta$  T-cell lymphoma, pp 161-162;  
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, pp 163-164;  
Primary cutaneous CD4+ small/medium T-cell lymphoma, pp 165-166;  
Subcutaneous panniculitis-like T-cell lymphoma, pp 186-187;  
In: Aster JC, Pozdnyakova O, Kutok JL. Hematopathology, High-Yield Pathology Series, Saunders Elsevier, 2013.
3. Duncan LM, **Elco CP**, Goyal A. Cutaneous Lymphoma Module, Dermpathpro.com, www, 2014.

**INVITED PRESENTATIONS**

1. Pathology Pitfalls and Deciphering Flow Cytometry. Cutaneous Lymphoma Continuing Medical Education Course, Dana Farber Cancer Institute, Nov 12, 2016.

**GRANTS**

2015	NIH Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship (F32). Molecular Alterations Characterizing Disease Progression of Cutaneous T Cell Lymphoma
2004	UNCF•Merck Graduate Science Research Dissertation Fellowship

**INVENTIONS**

Date: Flory JP, **Elco CP**. "72 Well Polypropylene Plate for Isco Foxy Fraction Collectors."